{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:11:39Z","timestamp":1778739099054,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"French ministry of health","award":["PHRC-15-260"],"award-info":[{"award-number":["PHRC-15-260"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-026-05965-3","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T14:41:11Z","timestamp":1775140871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Amikacin pharmacokinetics after nebulization among intubated patients"],"prefix":"10.1186","volume":"30","author":[{"given":"Nicolas","family":"Gregoire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Quenot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Etienne","family":"Herbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micka\u00ebl","family":"Landais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Veinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Dahyot-Fizelier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie Heuz\u00e9","family":"Vourc\u2019h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Respaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Ehrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Reva network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"CRICS-TRIGGERSEP F-CRIN research network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"5965_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40262-015-0250-x","volume":"54","author":"C Stockmann","year":"2015","unstructured":"Stockmann C, Roberts JK, Yellepeddi VK, Sherwin CM. Clinical pharmacokinetics of inhaled antimicrobials. Clin Pharmacokinet. 2015;54:473\u201392.","journal-title":"Clin Pharmacokinet"},{"key":"5965_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1021\/acs.molpharmaceut.3c00685","volume":"21","author":"JE Hastedt","year":"2024","unstructured":"Hastedt JE, B\u00e4ckman P, Cabal A, Clark A, Ehrhardt C, Forbes B, Hickey AJ, Hochhaus G, Jiang W, Kassinos S, Kuehl PJ, Prime D, Son YJ, Teague S, Tehler U, Wylie J. iBCS: 3. A Biopharmaceutics Classification System for Orally Inhaled Drug Products. Mol Pharm. 2024;21:164\u201372.","journal-title":"Mol Pharm"},{"key":"5965_CR3","doi-asserted-by":"publisher","first-page":"e01261","DOI":"10.1128\/AAC.01261-18","volume":"62","author":"S Marchand","year":"2018","unstructured":"Marchand S, Boisson M, Mehta S, Adier C, Mimoz O, Gregoire N, Couet W. Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 6. Aminoglycosides. Antimicrob Agents Chemother. 2018;62:e01261\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"5965_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s11517-015-1408-2","volume":"54","author":"M Alzahrany","year":"2016","unstructured":"Alzahrany M, Van Rhein T, Banerjee A, Salzman G. Fluid flow and particle transport in mechanically ventilated airways. Part II: particle transport. Med Biol Eng Comput. 2016;54:1097\u2013109.","journal-title":"Med Biol Eng Comput"},{"key":"5965_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00003246-198502000-00005","volume":"13","author":"NR MacIntyre","year":"1985","unstructured":"MacIntyre NR, Silver RM, Miller CW, Schuler F, Coleman RE. Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med. 1985;13:81\u20134.","journal-title":"Crit Care Med"},{"key":"5965_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1089\/jamp.2011.0936","volume":"25","author":"A Ari","year":"2012","unstructured":"Ari A, Fink JB, Dhand R. Inhalation therapy in patients receiving mechanical ventilation: an update. J Aerosol Med Pulm Drug Deliv. 2012;25:319\u201332.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"5965_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13613-017-0301-6","volume":"7","author":"S Ehrmann","year":"2017","unstructured":"Ehrmann S, Chastre J, Diot P, Lu Q. Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care. Ann Intensive Care. 2017;7:78.","journal-title":"Ann Intensive Care"},{"key":"5965_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13613-023-01220-y","volume":"13","author":"J Dugernier","year":"2023","unstructured":"Dugernier J, Le Pennec D, Maerckx G, Allimonnier L, Hesse M, Castanares-Zapatero D, Depoortere V, Vecellio L, Reychler G, Michotte JB, Goffette P, Docquier MA, Raftopoulos C, Jamar F, Laterre PF, Ehrmann S, Wittebole X. Inhaled drug delivery: a randomized study in intubated patients with healthy lungs. Ann Intensive Care. 2023;13:125.","journal-title":"Ann Intensive Care"},{"key":"5965_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13613-016-0169-x","volume":"6","author":"J Dugernier","year":"2016","unstructured":"Dugernier J, Reychler G, Wittebole X, Roeseler J, Depoortere V, Sottiaux T, Michotte JB, Vanbever R, Dugernier T, Goffette P, Docquier MA, Raftopoulos C, Hantson P, Jamar F, Laterre PF. Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study. Ann Intensive Care. 2016;6:73.","journal-title":"Ann Intensive Care"},{"key":"5965_CR10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.21037\/atm-20-5665","volume":"9","author":"HL Lin","year":"2021","unstructured":"Lin HL, Fink JB, Ge H. Aerosol delivery via invasive ventilation: a narrative review. Ann Transl Med. 2021;9:588.","journal-title":"Ann Transl Med"},{"key":"5965_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s13054-018-1958-4","volume":"22","author":"A Torres","year":"2018","unstructured":"Torres A, Motos A, Battaglini D, Li Bassi G. Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects. Crit Care. 2018;22:343.","journal-title":"Crit Care"},{"key":"5965_CR12","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.chest.2016.11.026","volume":"151","author":"MH Kollef","year":"2017","unstructured":"Kollef MH, Ricard JD, Roux D, Francois B, Ischaki E, Rozgonyi Z, Boulain T, Ivanyi Z, J\u00e1nos G, Garot D, Koura F, Zakynthinos E, Dimopoulos G, Torres A, Danker W, Montgomery AB. A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial. Chest. 2017;151:1239\u201346.","journal-title":"Chest"},{"key":"5965_CR13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S1473-3099(20)30481-3","volume":"20","author":"JJ Rouby","year":"2020","unstructured":"Rouby JJ, Monsel A, Ehrmann S, Bougl\u00e9 A, Laterre PF. The INHALE trial: multiple reasons for a negative result. Lancet Infect Dis. 2020;20:778\u20139.","journal-title":"Lancet Infect Dis"},{"key":"5965_CR14","doi-asserted-by":"crossref","unstructured":"Ehrmann S, Barbier F, Demiselle J, Quenot JP, Herbrecht JE, Roux D, Lacherade JC, Landais M, Seguin P, Schnell D, Veinstein A, Gouin P, Lasocki S, Lu Q, Beduneau G, Ferrandiere M, Plantef\u00e8ve G, Dahyot-Fizelier C, Chebib N, Mercier E, Heuz\u00e9-Vourc\u2019h N, Respaud R, Gregoire N, Garot D, Nay MA, Meziani F, Andreu P, Clere-Jehl R, Zucman N, Aza\u00efs MA, Saint-Martin M, Gandonni\u00e8re CS, Benzekri D, Merdji H, Tavernier E. Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia. N Engl J Med. 2023;389:2052\u201362.","DOI":"10.1056\/NEJMoa2310307"},{"key":"5965_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00134-010-1879-4","volume":"36","author":"Q Lu","year":"2010","unstructured":"Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin MH, Le Naour G, Marquette CH, Rouby JJ. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 2010;36:1147\u201355.","journal-title":"Intensive Care Med"},{"key":"5965_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1089\/jamp.2010.0860","volume":"24","author":"CE Luyt","year":"2011","unstructured":"Luyt CE, Eldon MA, Stass H, Gribben D, Corkery K, Chastre J. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure. J Aerosol Med Pulm Drug Deliv. 2011;24:183\u201390.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"5965_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1089\/jamp.2013.1100","volume":"27","author":"AB Montgomery","year":"2014","unstructured":"Montgomery AB, Vallance S, Abuan T, Tservistas M, Davies A. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow\u00ae inline nebulizer system in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv. 2014;27:441\u20138.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"5965_CR18","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1093\/jac\/dkw313","volume":"71","author":"A Petitcollin","year":"2016","unstructured":"Petitcollin A, Dequin PF, Darrouzain F, Vecellio L, Boulain T, Garot D, Paintaud G, Ternant D, Ehrmann S. Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients. J Antimicrob Chemother. 2016;71:3482\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"5965_CR19","doi-asserted-by":"publisher","first-page":"R200","DOI":"10.1186\/cc8206","volume":"13","author":"CE Luyt","year":"2009","unstructured":"Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, Corkery K, Gribben D, Chastre J. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care. 2009;13:R200.","journal-title":"Crit Care"},{"key":"5965_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00134-011-2420-0","volume":"38","author":"MS Niederman","year":"2012","unstructured":"Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, Garc\u00eda MS. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012;38:263\u201371.","journal-title":"Intensive Care Med"},{"key":"5965_CR21","doi-asserted-by":"publisher","first-page":"e048591","DOI":"10.1136\/bmjopen-2020-048591","volume":"11","author":"E Tavernier","year":"2021","unstructured":"Tavernier E, Barbier F, Meziani F, Quenot JP, Herbrecht JE, Landais M, Roux D, Seguin P, Schnell D, Veinstein A, Veber B, Lasocki S, Lu Q, Beduneau G, Ferrandiere M, Dahyot-Fizelier C, Plantefeve G, Nay MA, Merdji H, Andreu P, Vecellio L, Muller G, Cabrera M, Le Pennec D, Respaud R, Lanotte P, Gregoire N, Leclerc M, Helms J, Boulain T, Lacherade JC, Ehrmann S. Inhaled amikacin versus placebo to prevent ventilator-associated pneumonia: the AMIKINHAL double-blind multicentre randomised controlled trial protocol. BMJ open. 2021;11:e048591.","journal-title":"BMJ open"},{"key":"5965_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S1473-3099(19)30574-2","volume":"20","author":"MS Niederman","year":"2020","unstructured":"Niederman MS, Alder J, Bassetti M, Boateng F, Cao B, Corkery K, Dhand R, Kaye KS, Lawatscheck R, McLeroth P, Nicolau DP, Wang C, Wood GC, Wunderink RG, Chastre J. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infect Dis. 2020;20:330\u201340.","journal-title":"Lancet Infect Dis"},{"key":"5965_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.00133-06","volume":"52","author":"S Kiem","year":"2008","unstructured":"Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother. 2008;52:24\u201336.","journal-title":"Antimicrob Agents Chemother"},{"key":"5965_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.hrtlng.2017.08.004","volume":"46","author":"IOF Moustafa","year":"2017","unstructured":"Moustafa IOF, Ali MRAA, Al Hallag M, Rabea H, Fink JB, Dailey P, Abdelrahim MEA. Lung deposition and systemic bioavailability of different aerosol devices with and without humidification in mechanically ventilated patients. Heart Lung. 2017;46:464\u20137.","journal-title":"Heart Lung"},{"key":"5965_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s13318-020-00669-7","volume":"46","author":"CM Rubino","year":"2021","unstructured":"Rubino CM, Onufrak NJ, van Ingen J, Griffith DE, Bhavnani SM, Yuen DW, Mange KC, Winthrop KL. Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease. Eur J Drug Metab Pharmacokinet. 2021;46:277\u201387.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"5965_CR26","doi-asserted-by":"crossref","unstructured":"Duong A, Simard C, Wang YL, Williamson D, Marsot A. Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling? Antibiotics. 2021;10:507.","DOI":"10.3390\/antibiotics10050507"},{"key":"5965_CR27","doi-asserted-by":"publisher","first-page":"106219","DOI":"10.1016\/j.ejps.2022.106219","volume":"175","author":"SE Medell\u00edn-Garibay","year":"2022","unstructured":"Medell\u00edn-Garibay SE, Romano-Aguilar M, Parada A, Su\u00e1rez D, Romano-Moreno S, Barcia E, Cervero M, Garc\u00eda B. Amikacin pharmacokinetics in elderly patients with severe infections. Eur J Pharm Sci. 2022;175:106219.","journal-title":"Eur J Pharm Sci"},{"key":"5965_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00228-014-1766-y","volume":"71","author":"C Burdet","year":"2015","unstructured":"Burdet C, Pajot O, Couffignal C, Armand-Lef\u00e8vre L, Foucrier A, Laou\u00e9nan C, Wolff M, Massias L, Mentr\u00e9 F. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Eur J Clin Pharmacol. 2015;71:75\u201383.","journal-title":"Eur J Clin Pharmacol"},{"key":"5965_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jiac.2020.09.033","volume":"27","author":"T Yamada","year":"2021","unstructured":"Yamada T, Fujii S, Shigemi A, Takesue Y. A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity. J Infect Chemother. 2021;27:256\u201361.","journal-title":"J Infect Chemother"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-026-05965-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-05965-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-05965-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:32:44Z","timestamp":1778736764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13054-026-05965-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5965"],"URL":"https:\/\/doi.org\/10.1186\/s13054-026-05965-3","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial protocol, including pharmacokinetic analyses was approved by a national ethics committee (comit\u00e9 de protection des personnes Ouest I, no. 2016-R29), all patients provided written informed consent in accordance with French law and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FB declares lecture fees from MSD and Advanz Pharma, consulting fees from Shionogi, conference invitation from Pfizer, and research grant from MSD and Aerogen. SE declares consultancies, travel support, lecture fees for Aerogen Ltd, travel support and lecture fees for Fisher & Paykel Healthcare, and intellectual property licensed to JIB smart home.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"250"}}